Agios Pharmaceuticals (NASDAQ:AGIO) Hits New 12-Month High – Should You Buy?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)’s stock price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $53.81 and last traded at $53.60, with a volume of 569806 shares traded. The stock had previously closed at $51.59.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, November 1st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. Royal Bank of Canada restated an “outperform” rating and set a $55.00 price objective on shares of Agios Pharmaceuticals in a research report on Friday, November 1st. Scotiabank raised their target price on Agios Pharmaceuticals from $51.00 to $53.00 and gave the stock a “sector outperform” rating in a research report on Friday, November 1st. Finally, Leerink Partnrs downgraded shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $52.33.

Agios Pharmaceuticals Stock Up 6.8 %

The stock has a fifty day simple moving average of $44.71 and a 200-day simple moving average of $42.61. The company has a market capitalization of $3.14 billion, a P/E ratio of 4.54, a PEG ratio of 0.45 and a beta of 0.75.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the sale, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.93% of the stock is currently owned by insiders.

Institutional Trading of Agios Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Acadian Asset Management LLC bought a new position in shares of Agios Pharmaceuticals in the second quarter valued at about $37,000. Quest Partners LLC bought a new position in shares of Agios Pharmaceuticals in the second quarter worth about $40,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 363 shares during the last quarter. CWM LLC lifted its position in shares of Agios Pharmaceuticals by 554.7% during the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 1,836 shares in the last quarter. Finally, North Star Asset Management Inc. bought a new stake in shares of Agios Pharmaceuticals during the second quarter valued at approximately $216,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.